H.C. Wainwright notes that on July 30 the American Journal of Hematology published results of a single-center, retrospective case-control study evaluating the impact of eculizumab on infection risk and infection-related mortality in pediatric patients diagnosed with thrombotic microangiopathy following allogeneic hematopoietic cell transplantation. Given that the AJH study raised caution about the potential increase in infections, complications and risk of death in using eculizumab in TA-TMA patients, the analyst believes the study could be a tailwind to narsoplimab uptake if the product is approved later this year. H.C. Wainwright has Buy rating and $9 price target on Omeros (OMER) shares.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OMER:
- Potential Market Surge for Omeros Driven by Narsoplimab’s Edge Over Eculizumab
- Omeros Enters Securities Purchase Agreement with Polar
- Omeros to sell 5.366M shares at $4.10 in registered direct offering
- Omeros submission adds another 2026 catalyst, says H.C. Wainwright
- Omeros submits narsoplimab marketing authorization application to the EMA